肝素
遗产管理(遗嘱认证法)
医学
麻醉
外科
政治学
法学
作者
Atsutaka Aratame,Tsuyoshi Baba,Hirokazu Minamimura,Yukihiro Nishimoto,Ryo Nangoya
出处
期刊:PubMed
日期:2024-06-01
卷期号:77 (6): 454-456
摘要
The management of patients on direct oral anticoagulants (DOACs) who require an emergency cardiac surgery has been disputed in Japan. Recently, the use of andexanet alfa as an antidote for apixaban and rivaroxaban, is approved in the setting of life-threating or uncontrollable major bleeding. However, the efficacy and safety of andexanet alfa have been investigated. We report a case of 72-year-old man taking rivaroxaban who required the emergency coronary artery bypass grafting. He received andexanet alfa prior to the operation. Heparin resistance was noted before starting cardiopulmonary bypass. Consideration should be given to the use of andexanet alfa before or during cardiopulmonary bypass.
科研通智能强力驱动
Strongly Powered by AbleSci AI